I cannot stress any further. Nova results now is before factory opening. Still, its profit is rising and able to offset IPO cost, plus higher admin expense due to enlarged company
The Board is of the opinion that the Revision and the Extension of Time will contribute positively to
the financial performance of the Group, will not be detrimental to the Group’s existing business
operations and is in the best interest of the Group.
The three products are all early stage (pre-clinical or phase 1) and not important product lines
The blockbuster drug is hepar-p "The remaining IPO Proceeds allocated for R&D activities amounting to RM2.50 million shall continue to be used for the third clinical trial for Hepar-P Capsule as originally planned."
And the true test is phase 3 (moderna covid19 vaccine is at clinical trials phase 3 and look at it skyrocket)
Nova is a true biotech company pursuing phase 3 clinical trials for hepar-p which is a cure for non-alcoholic liver disease which has no cure currently, it is not your generic pharmaceutical company protected by the government via direct contracts. Just look at its class leading margins
this stock kena goreng guys.. Its because gov announce pharma and dpharma is the only one that can sell covid vaccine. So whole pharma sector got goreng up
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Invest_888
1,067 posts
Posted by Invest_888 > 2020-05-29 10:07 | Report Abuse
Next quarter should be much better according to previous analysis. New GMP plant, high profit margin & good cash flow are another bonus.